Source: Microba
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Microba Life Sciences (MAP) signs a strategic partnership agreement with healthcare company, Midnight Health, to deliver personalised health service to the Australian market
  • The agreement will see the companies collaborate on a new subscription based service, known as Vidality
  • The service aims to leverage its network of pharmacists to formulate personalised supplements based on customers microbiome test results
  • Shares are trading two per cent lower today at 24.5 cents each at market close

Microba Life Sciences (MAP) has signed a strategic partnership agreement with healthcare company, Midnight Health, to deliver personalised health services to the Australian market.

The agreement will see the companies collaborate to promote, market, and sell a new subscription based service, known as Vidality.

The service aims to leverage its network of pharmacists to formulate personalised supplements based on customers microbiome test results.

Chief Executive Officer Dr Luke Reid is pleased with the agreement.

“Consumers are seeking personalised, evidence-based solutions to support their gut health,” he said.

“Together with Midnight Health, we are excited to bring the Vidality product to consumers, a truly personalised solution powered by our technology.”

Shares were trading two per cent lower today at 24.5 cents each at market close.

MAP by the numbers
More From The Market Online
Market Close Graphic

ASX Market Close: Another reversal as just-green Oz markets ignore US dive | Jan 3, 2024

The Aussie bourse has defied morning expectations for the second time in as many days, closing out all but flat with a 0.
A Red Sky Energy rig out in the ocean.

Red Sky Energy bleeds more than 18% after ‘landmark’ Angola block entry

Red Sky Energy was ready to pop champagne after being awarded 35% in a "transformative" Angola…
A patient being dosed with Imugene Limited testing materials.

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic
A market trading board with ASX marked on the side.

‘Shine a light’: ASX to get more aggressive on companies ‘not up to scratch’ on disclosures

The Australian Securities Exchange (ASX:ASX) will be taking poor disclosure from market-listed companies far more seriously through this next